Found: 109
Select item for more details and to access through your institution.
A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies.
- Published in:
- Investigational New Drugs, 2020, v. 38, n. 2, p. 445, doi. 10.1007/s10637-019-00780-w
- By:
- Publication type:
- Article
Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 4, p. 763, doi. 10.1007/s10637-018-0710-x
- By:
- Publication type:
- Article
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 3, p. 567, doi. 10.1007/s10637-018-0707-5
- By:
- Publication type:
- Article
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 3, p. 584, doi. 10.1007/s10637-018-0681-y
- By:
- Publication type:
- Article
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patients.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 6, p. 1072, doi. 10.1007/s10637-018-0658-x
- By:
- Publication type:
- Article
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 4, p. 732, doi. 10.1007/s10637-018-0598-5
- By:
- Publication type:
- Article
Germline <italic>BRCA</italic> mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 1, p. 163, doi. 10.1007/s10637-017-0497-1
- By:
- Publication type:
- Article
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 2, p. 271, doi. 10.1007/s10637-013-9983-2
- By:
- Publication type:
- Article
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 2, p. 355, doi. 10.1007/s10637-013-0057-2
- By:
- Publication type:
- Article
Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.
- Published in:
- 2013
- By:
- Publication type:
- Report
Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure.
- Published in:
- 2012
- By:
- Publication type:
- Report
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 819, doi. 10.1007/s10637-010-9593-1
- By:
- Publication type:
- Article
A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 2, p. 366, doi. 10.1007/s10637-009-9363-0
- By:
- Publication type:
- Article
The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study.
- Published in:
- 2010
- By:
- Publication type:
- journal article
Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer.
- Published in:
- European Radiology, 2021, v. 31, n. 2, p. 864, doi. 10.1007/s00330-020-07134-8
- By:
- Publication type:
- Article
Consideration of aggressive therapeutic strategies for primary testicular lymphoma.
- Published in:
- American Journal of Hematology, 2007, v. 82, n. 9, p. 840, doi. 10.1002/ajh.20973
- By:
- Publication type:
- Article
Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases.
- Published in:
- American Journal of Hematology, 2007, v. 82, n. 6, p. 446, doi. 10.1002/ajh.20874
- By:
- Publication type:
- Article
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib.
- Published in:
- Hepatology Research, 2021, v. 51, n. 7, p. 796, doi. 10.1111/hepr.13669
- By:
- Publication type:
- Article
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 38, doi. 10.1159/000519867
- By:
- Publication type:
- Article
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 3, p. 275, doi. 10.1159/000515553
- By:
- Publication type:
- Article
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis.
- Published in:
- Liver Cancer (2235-1795), 2020, v. 9, n. 5, p. 613, doi. 10.1159/000508901
- By:
- Publication type:
- Article
Correction to: Efficacy and Safety Results from a Phase 2, Randomized, Double Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- Clinical Drug Investigation, 2021, v. 41, n. 9, p. 795, doi. 10.1007/s40261-021-01063-0
- By:
- Publication type:
- Article
Kinetics of the neutrophil‐lymphocyte ratio during PD‐1 inhibition as a prognostic factor in advanced hepatocellular carcinoma.
- Published in:
- Liver International, 2021, v. 41, n. 9, p. 2189, doi. 10.1111/liv.14932
- By:
- Publication type:
- Article
Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma.
- Published in:
- Liver International, 2021, v. 41, n. 6, p. 1398, doi. 10.1111/liv.14813
- By:
- Publication type:
- Article
Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study.
- Published in:
- Liver International, 2020, v. 40, n. 10, p. 2544, doi. 10.1111/liv.14573
- By:
- Publication type:
- Article
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events.
- Published in:
- Liver International, 2020, v. 40, n. 9, p. 2263, doi. 10.1111/liv.14496
- By:
- Publication type:
- Article
Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221097934
- By:
- Publication type:
- Article
Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221097190
- By:
- Publication type:
- Article
ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211039928
- By:
- Publication type:
- Article
Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211003053
- By:
- Publication type:
- Article
Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biomarker analysis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
- Published in:
- Gastric Cancer, 2019, v. 22, n. 3, p. 527, doi. 10.1007/s10120-018-0891-1
- By:
- Publication type:
- Article
Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis.
- Published in:
- Gastric Cancer, 2017, v. 20, n. 6, p. 970, doi. 10.1007/s10120-017-0710-0
- By:
- Publication type:
- Article
Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
- Published in:
- Gastric Cancer, 2017, v. 20, n. 1, p. 182, doi. 10.1007/s10120-015-0580-2
- By:
- Publication type:
- Article
Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
- Published in:
- Gastric Cancer, 2017, v. 20, n. 1, p. 146, doi. 10.1007/s10120-015-0586-9
- By:
- Publication type:
- Article
Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 2, p. 579, doi. 10.1007/s10120-015-0503-2
- By:
- Publication type:
- Article
Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 1, p. 226, doi. 10.1007/s10120-015-0464-5
- By:
- Publication type:
- Article
Improving trends in survival of patients who receive chemotherapy for metastatic or recurrent gastric cancer: 12 years of experience at a single institution.
- Published in:
- Gastric Cancer, 2015, v. 18, n. 2, p. 346, doi. 10.1007/s10120-014-0385-8
- By:
- Publication type:
- Article
Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.
- Published in:
- Gastric Cancer, 2012, v. 15, n. 3, p. 305, doi. 10.1007/s10120-011-0117-2
- By:
- Publication type:
- Article
A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity.
- Published in:
- Oncology, 2012, v. 82, n. 5, p. 290, doi. 10.1159/000337989
- By:
- Publication type:
- Article
Sorafenib Dose Escalation in the Treatment of Advanced Hepatocellular Carcinoma.
- Published in:
- Oncology, 2012, v. 82, n. 2, p. 119, doi. 10.1159/000336082
- By:
- Publication type:
- Article
Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1.
- Published in:
- Gastroenterology Research & Practice, 2015, p. 1, doi. 10.1155/2016/6857625
- By:
- Publication type:
- Article
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Clinical outcomes of immune checkpoint inhibitors in unresectable or metastatic combined hepatocellular–cholangiocarcinoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7547, doi. 10.1007/s00432-023-04704-3
- By:
- Publication type:
- Article
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 12, p. 3665, doi. 10.1007/s00432-021-03602-w
- By:
- Publication type:
- Article
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 747, doi. 10.1634/theoncologist.2018-0838
- By:
- Publication type:
- Article
A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer.
- Published in:
- Oncologist, 2017, v. 22, n. 2, p. 129, doi. 10.1634/theoncologist.2016-0273
- By:
- Publication type:
- Article
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
- Published in:
- Acta Oncologica, 2012, v. 51, n. 4, p. 528, doi. 10.3109/0284186X.2011.636753
- By:
- Publication type:
- Article